Learning

February 12, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA HEIH  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 10.21 pm

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
February 12, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA  ILF3-AS1  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 9.56 pm

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
February 10, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA ATB increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 11/Februay/2019, 12.19 am

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
February 9, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA ZFAS1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 9/Februay/2019, 7.01 am

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]